ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Holding ANIP?
Track your performance easily

ANI Pharmaceuticals (ANIP) Ownership - Who Owns ANI Pharmaceuticals?

283 Followers

ANI Pharmaceuticals (ANIP) Ownership Overview

10.00%18.20%2.13%22.21%47.46%
10.00% Insiders
2.13% Other Institutional Investors
22.21% ETFs
47.46% Public Companies and
Individual Investors
The ownership structure of ANI Pharmaceuticals (ANIP) stock is a mix of institutional, retail, and individual investors. Approximately 42.54% of the company’s stock is owned by Institutional Investors, 10.00% is owned by Insiders, and 47.46% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 06, 2024
xxxxxxxxxxxxx
$317900
Jun 06, 2024
Ori Gutwerg
Svp, Generics
xxxxxxxxxxxxx
$199995
May 22, 2024
Christopher Mutz
Head Of Rare Disease
xxxxxxxxxxxxx
$123220
May 17, 2024
xxxxxxxxxxxxx
$127740

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
1,997,954Institution9.50%116,260,943
1,082,040Institution5.15%62,963,908
831,537Institution3.95%48,387,138
706,272Insider3.36%41,097,968
557,343Institution2.65%32,431,789
373,859Insider1.78%21,754,855
350,387Institution1.67%20,389,020
326,067Institution1.55%18,973,839
305,559Institution1.45%17,780,478
263,159Institution1.25%15,313,222

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
831,537Institution3.95%48,387,138
350,387Institution1.67%20,389,020
326,067Institution1.55%18,973,839
263,159Institution1.25%15,313,222
206,405Institution0.98%12,010,707
194,910Institution0.93%11,341,813
162,932Institution0.77%9,481,013
154,168Institution0.73%8,971,036
115,708Institution0.55%6,733,049
113,437Institution0.54%6,600,899

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,057,588Institution5.03%61,541,046
588,253Institution2.80%35,095,174
555,702Institution2.64%31,811,161
470,136Institution2.24%27,357,214
245,955Institution1.17%14,673,675
160,951Institution0.77%9,365,739
147,639Institution0.70%8,591,113
146,254Institution0.70%8,372,310
115,688Institution0.55%6,731,885
89,256Institution0.42%5,109,460

FAQ

Who Owns ANI Pharmaceuticals Inc (ANIP)?
According to the latest TipRanks data, approximately 2.13% of the company's stock is held by institutional investors, 10.00% is held by insiders, and 47.46% is held by retail investors.
    What percentage of ANI Pharmaceuticals Inc (ANIP) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.13% of ANI Pharmaceuticals Inc (ANIP) stock is held by institutional investors.
      What percentage of ANI Pharmaceuticals Inc (ANIP) stock is held by retail investors?
      According to the latest TipRanks data, approximately 47.46% of ANI Pharmaceuticals Inc (ANIP) stock is held by retail investors.
        Who owns the most shares of ANI Pharmaceuticals Inc (ANIP)?
        iShares owns the most shares of ANI Pharmaceuticals Inc (ANIP).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis